127 related articles for article (PubMed ID: 36038129)
21. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.
Mehta N; Kotwani P; Norman J; Shui A; Li PJ; Saxena V; Chan W; Yao FY
Liver Transpl; 2023 Oct; 29(10):1041-1049. PubMed ID: 37159217
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
23. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
Goldman ML; Zhou K; Dodge JL; Yao F; Mehta N
Liver Transpl; 2022 May; 28(5):763-773. PubMed ID: 34927344
[TBL] [Abstract][Full Text] [Related]
24. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
25. Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout.
Piñero F; Thompson M; Boin I; Chagas A; Quiñonez E; Bermúdez C; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Perales SR; Maccali C; Vergara Sandoval R; McCormack L; Varón A; Marciano S; Mattera J; Carrilho F; Silva M
Liver Int; 2022 Aug; 42(8):1879-1890. PubMed ID: 35304813
[TBL] [Abstract][Full Text] [Related]
26. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
27. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
28. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
29. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
30. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
[TBL] [Abstract][Full Text] [Related]
32. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times.
Squires MH; Hanish SI; Fisher SB; Garrett C; Kooby DA; Sarmiento JM; Cardona K; Adams AB; Russell MC; Magliocca JF; Knechtle SJ; Staley CA; Maithel SK
J Surg Oncol; 2014 May; 109(6):533-41. PubMed ID: 24347475
[TBL] [Abstract][Full Text] [Related]
33. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
[TBL] [Abstract][Full Text] [Related]
34. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria.
Ravaioli M; Grazi GL; Piscaglia F; Trevisani F; Cescon M; Ercolani G; Vivarelli M; Golfieri R; D'Errico Grigioni A; Panzini I; Morelli C; Bernardi M; Bolondi L; Pinna AD
Am J Transplant; 2008 Dec; 8(12):2547-57. PubMed ID: 19032223
[TBL] [Abstract][Full Text] [Related]
35. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
[TBL] [Abstract][Full Text] [Related]
36. Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients.
Daoud A; Soliman K; Teeter L; Ali H; Graviss EA; Mogawer S; Sholkamy A; El-Shazli M; Gaber AO
Transplant Proc; 2021 Apr; 53(3):833-838. PubMed ID: 33589231
[TBL] [Abstract][Full Text] [Related]
37. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
38. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
39. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
40. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.
Leung JY; Zhu AX; Gordon FD; Pratt DS; Mithoefer A; Garrigan K; Terella A; Hertl M; Cosimi AB; Chung RT
Liver Transpl; 2004 Nov; 10(11):1343-54. PubMed ID: 15497158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
